Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences
May 28, 2019 16:30 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., May 28, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that Scott Garland, Portola’s president and chief executive officer, will...
Portola Pharmaceuticals Announces New Analysis from the ANNEXA-4 Study of its Factor Xa Inhibitor Reversal Agent Andexxa® in Patients with Spontaneous (Non-Traumatic) Intracranial Hemorrhage
May 22, 2019 10:45 ET
|
Portola Pharmaceuticals, Inc.
– Excellent or Good Hemostasis Achieved in 79% of Evaluable Patients with Spontaneous Intracranial Hemorrhage – – Data Featured in an Oral Presentation at the 5th European Stroke Organisation...
Portola Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 08, 2019 08:01 ET
|
Portola Pharmaceuticals, Inc.
– First Quarter Revenues of $22.2 Million; Andexxa® Product Revenues Grow 45% to $20.3 Million – – European Commission Approval of Ondexxya®; Staged Commercial Launch Planned in Second Half of 2019 –...
European Commission Grants Conditional Marketing Authorization for Portola Pharmaceuticals’ Ondexxya™ (andexanet alfa), the First and Only Antidote for the Reversal of Factor Xa Inhibitors
April 26, 2019 14:00 ET
|
Portola Pharmaceuticals, Inc.
– Major Advance in the Treatment of European Factor Xa Inhibitor Patients Hospitalizedwith Life-Threatening Bleeding – – Initial Launch in Select Countries to Begin 2H 2019 – SOUTH SAN FRANCISCO,...
Portola Pharmaceuticals Announces Retirement of Dr. John Curnutte, Executive Vice President and Head of Research and Development
April 24, 2019 08:30 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., April 24, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that Dr. John Curnutte, M.D., Ph.D., Executive Vice President and Head...
Portola Pharmaceuticals to Announce First Quarter 2019 Financial Results on Wednesday, May 8, 2019
April 17, 2019 16:15 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., April 17, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company’s...
Portola Pharmaceuticals’ Co-Founder Dr. Charles Homcy Retires from the Company’s Board of Directors
March 20, 2019 17:00 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., March 20, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that on March 15, 2019 Charles Homcy, M.D., informed the Board of his...
Portola Pharmaceuticals to Webcast Presentation at Cowen and Company’s 39th Annual Health Care Conference
March 06, 2019 16:10 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that Scott Garland, Portola’s president and chief executive officer,...
Portola Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
March 01, 2019 08:05 ET
|
Portola Pharmaceuticals, Inc.
– Fourth Quarter Andexxa® Revenues of $14.0 Million; Third Consecutive Quarter of Strong Revenues – – Received Positive CHMP Opinion on Ondexxya™; European Commission Decision Anticipated in Early...
Portola Pharmaceuticals Enters into $125 Million Loan Agreement with HealthCare Royalty Partners and Athyrium Capital Management
March 01, 2019 08:03 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., March 01, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that it has entered into a $125 million loan agreement with HealthCare...